Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
: ( , )
Women in menopause taking both semaglutide and hormone replacement therapy (HRT) lost 16 percent of their body weight (a statistically significant difference)
GLP-1 receptor agonists are licensed in the UK for type 2 diabetes and weight management, including semaglutide, dulaglutide, and liraglutide These medications reduce HbA1c by approximately 1.01.5 percentage points and improve both fasting and post-meal glucose levels Weight loss associated with GLP-1 therapy can lead to secondary improvements in insulin resistance, particularly through reduction of visceral fat Common side effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhoea, which typically diminish over several weeks NICE recommends continuation only if patients achieve at least 1.0 percentage point HbA1c reduction within six months of treatment initiation Patients with diabetic retinopathy require close monitoring, and GLP-1 medications should be discontinued at least two months before planned pregnancy Table of Contents What Are GLP-1 Receptor Agonists and How Do They Work
When comparing liraglutide and semaglutide GLP-1, the latter is considered more effective for weight loss
